Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia

Bone Marrow Transplantation

Volumn 48, Issue 5, 2013, Pages 666-670

  Poon, L M ^a   Bassett Jr , R ^a   Rondon, G ^a   Hamdi, A ^a   Qazilbash, M ^a   Hosing, C ^a   Jones, R B ^a   Shpall, E J ^a   Popat, U R ^a   Nieto, Y ^a   Worth, L L ^a   Cooper, L ^a   De Lima, M ^a   Champlin, R E ^a   Kebriaei, P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

ALL; allogeneic transplant; second

Indexed keywords

ASPARAGINASE; CLOFARABINE; NELARABINE; PROTEIN TYROSINE KINASE INHIBITOR; STEROID; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CAUSE OF DEATH; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE INTERVAL; DONOR; DONOR LYMPHOCYTE INFUSION; FOLLOW UP; HUMAN; INCIDENCE; LEUKEMIA RELAPSE; LONG TERM SURVIVAL; LUNG DISEASE; MAJOR CLINICAL STUDY; MORTALITY; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REMISSION; RETROSPECTIVE STUDY; SALVAGE THERAPY; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; SURVIVOR; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877648195     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.195     Document Type: Article

References (21)

1. Spyridonidis A, Labopin M, Schmid C, Volin L, Yakoub-Agha I, Stadler M et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia 2012; 26: 1211-1217.
2. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007; 109: 944-950.
3. Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004; 34: 721-727.
4. Bosi A, Laszlo D, Labopin M, Reffeirs J, Michallet M, Gluckman E et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001; 19: 3675-3684.
5. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007; 109: 3189-3197.
6. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633.
7. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
8. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
10. Jason PF, Gray RJA. Proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
11. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547-561.
12. Bosi A, Bacci S, Miniero R, Locatelli F, Laszlo D, Longo G et al. Second allogeneic bone marrow transplantation in acute leukemia: a multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). Leukemia 1997; 11: 420-424.
13. Mack M, Riethmuller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci 1995; 92: 7021-7025.
14. Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM et al. A recombinant bispecific single-chain antibody, CD19XCD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000; 95: 2098-2103.
15. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S et al. Targeted therapy with the T-Cell engaging antibody blinatumomab of chemotherapyrefractory minimal residual disease in b-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29: 2493-2498.
16. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 13: 403-411.
17. Topp MS, Goekbuget N, Zugmaier G, Viardot A, Stelljes M, Neumann S et al. Anti-CD19 BiTE blinatumomab induces high complete remission rate in adult patients with relapsed B-precursor ALL:Updated Results of An Ongoing Phase II Trial. ASH Annual Meeting Abstracts 118: 252.
18. Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumorspecific chimeric antigen receptor. Blood 2010; 116: 1035-1044.
19. Kebriaei P, Kelly SS, Manuri P, Jena B, Jackson R, Shpall E et al. CARs: driving T-cell specificity to enhance anti-tumor immunity. Front Biosci (Schol Ed), 2012; 4: 520-531.
20. Park JH, Sauter C, Brentjens R. Cellular therapies in acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2011; 25: 1281-1301.
21. Kishi K, Takahashi S, Gondo H, Shiobara S, Kanamaru A, Kato S et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes. Bone Marrow Transplant 1997; 19: 461-466.